Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 6Cisplatin 6Magnetic Resonance Spectroscopy 4Docetaxel 4Specimen Handling 3Radiotherapy, Intensity-Modulated 3Platinum 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3atezolizumab 2Radiotherapy 2Immunoglobulin G 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2Biopsy 2toripalimab 1nimotuzumab 1durvalumab 1bempegaldesleukin 1alfacalcidol 1acetyl-glycyl-asparagyl-glutaminyl-glutamyl-glutaminyl-valyl-seryl-prolyl-leucyl-threonyl-leucyl-leucyl-lysyl-lysyl-tryptophyl-cysteinyl-Alexa Fluoro 680 C2C2-maleimide conjugate 1X-Rays 1Sentinel Lymph Node Biopsy 1Radiotherapy, Image-Guided 1Photons 1Nivolumab 1Neck Dissection 1Fluconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Squamous Cell Carcinoma of Head and Neck × bempegaldesleukin × Clear all
NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Nektar Therapeutics

Phase 2/3 Terminated
1 enrolled 6 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡